Futibatinib is a targeted FGFR kinase inhibitor used to treat specific cancer patients. The following will provide a detailed explanation of its usage, dosage, and precautions for special populations to ensure the safety and effectiveness of clinical medication.

1. Usage and dosage

(1) Standard dose: The recommended dose is 20mg once daily, taken orally on an empty stomach (1 hour before or 2 hours after meals).

(2) Course of treatment: Continue treatment until disease progression or intolerable toxic reactions occur.

(3) Dose adjustment: Depending on the severity of adverse reactions, the dosage can be reduced to 15mg or 10mg once daily.

2. Medication for special populations

(1) Pregnancy period

Based on animal research results, Fubatinib may cause harm to fetuses. Before taking medication, it is necessary to confirm the pregnancy status, and effective contraceptive measures should be taken during the treatment period and one month after stopping the medication.

(2) Lactation period

There is currently no data indicating whether Fubatinib is secreted into human milk. It is recommended to suspend breastfeeding during the treatment period and within one week after the last administration.

(3) Pediatric patients

The safety and efficacy of using it for patients under 18 years old have not been established and is not recommended.

(4) Elderly patients

Patients over 65 years old need to be closely monitored as they may be more prone to adverse reactions.

(5) Liver dysfunction

Child Pugh Class A patients do not require dose adjustment; Child Pugh B patients are recommended to reduce their dosage by 50%; Child Pugh Class C patients are contraindicated.

(6) Renal insufficiency

Mild to moderate renal insufficiency (eGFR ≥ 30mL/min) does not require dose adjustment; Use with caution in patients with severe renal insufficiency (eGFR<30mL/min) or dialysis.

3. Precautions

(1) Ophthalmic examination: Regular ophthalmic examinations are conducted before and during treatment to monitor the risk of retinal lesions.

(2) Electrolyte monitoring: Regularly monitor blood phosphorus levels and promptly address hyperphosphatemia.

(3) Drug interactions: Avoid using potent CYP3A4 inhibitors or inducers in combination, and adjust the dosage if necessary.